Understand the source comparison
Melatonin Safety Profile: Clinical Evidence Comparison
The table below summarizes safety outcomes across different use patterns and populations based on peer-reviewed clinical trial data: Single-dose (0.3–1mg) No significant difference None detected Reduced sleep latency, no REM suppression Safest approach for occ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes safety outcomes across different use patterns and populations based on peer-reviewed clinical trial data:
- Single-dose (0.3–1mg)
- No significant difference
- None detected
- Reduced sleep latency, no REM suppression
- Safest approach for occasional use. Mimics physiological levels
- Short-term (<14 days, 3–5mg)
- 4–8% mild GI or headache (similar to placebo)
- Transient LH suppression in women (returns to baseline within 7 days)
- Improved sleep onset, minimal impact on sleep stages
- Low risk for acute intervention. Appropriate for jet lag or phase shifting
- Chronic use (>12 weeks, 5–10mg)
- 12–18% daytime drowsiness, 6–10% headache
- LH/FSH suppression 15–27%, reduced estradiol mid-cycle peaks
- Reduced sleep latency initially, returns to baseline by month 3–4 despite continued use
- Receptor desensitization observed. Benefits diminish while hormonal suppression persists
- Pediatric use (<18 years, any dose)
- 8–14% daytime irritability or mood changes
- Suppression of pubertal hormone signaling in animal models; human data insufficient
- Effective for neurodevelopmental sleep disorders but long-term CNS effects unknown
- Use only under medical supervision. Developing HPG axis may be vulnerable
- Elderly (>65 years, 2–5mg)
- No difference vs placebo in most trials
- Minimal impact on already-low reproductive hormones
- Improved sleep maintenance, less benefit for sleep onset
- Generally well-tolerated. Endogenous production already low, less receptor desensitization risk